2017
Can echogenic appearance of neuroendocrine liver metastases on intraoperative ultrasonography predict tumor biology and prognosis?
Dogeas E, Chong CCN, Weiss MJ, Ahuja N, Choti MA. Can echogenic appearance of neuroendocrine liver metastases on intraoperative ultrasonography predict tumor biology and prognosis? Hepato Pancreato Biliary 2017, 20: 237-243. PMID: 29103839, DOI: 10.1016/j.hpb.2017.08.029.Peer-Reviewed Original ResearchConceptsNeuroendocrine liver metastasesTumor biologyLiver metastasesShorter median disease-free survivalMedian disease-free survivalDisease-free survivalManagement of patientsPotential prognostic factorsSmaller tumor sizeLong-term outcomesHypoechoic metastasesAdditional metastasesPrognostic factorsClinicopathologic factorsSurgical interventionSurgical strategyPreoperative imagingTumor sizeHypoechoic lesionsIntraoperative ultrasonographyNeuroendocrine tumorsProspective dataHyperechoic lesionsTumor gradeBiologic behaviorCombination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study
Connolly RM, Li H, Jankowitz RC, Zhang Z, Rudek MA, Jeter SC, Slater SA, Powers P, Wolff AC, Fetting JH, Brufsky A, Piekarz R, Ahuja N, Laird PW, Shen H, Weisenberger DJ, Cope L, Herman JG, Somlo G, Garcia AA, Jones PA, Baylin SB, Davidson NE, Zahnow CA, Stearns V. Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study. Clinical Cancer Research 2017, 23: 2691-2701. PMID: 27979916, PMCID: PMC5457329, DOI: 10.1158/1078-0432.ccr-16-1729.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerObjective response rateCombination epigenetic therapyEstrogen receptorEndocrine therapyPrimary endpointPartial responseMulticenter phase II studyEpigenetic therapyAdditional partial responsesHormone-resistant diseasePhase II studyTime of progressionBreast cancer modelClin Cancer ResHistone deacetylase inhibitorsImportant therapeutic targetPosttreatment biopsiesTNBC cohortII studyBreast cancerDNA methyltransferase inhibitorTherapeutic targetResponse rateCancer modelA Four-Gene Promoter Methylation Marker Panel Consisting of GREM1, NEURL, LAD1, and NEFH Predicts Survival of Clear Cell Renal Cell Cancer Patients
van Vlodrop IJH, Joosten SC, De Meyer T, Smits KM, Van Neste L, Melotte V, Baldewijns MMLL, Schouten LJ, van den Brandt PA, Jeschke J, Yi JM, Schuebel KE, Ahuja N, Herman JG, Aarts MJ, Bosman FT, Van Criekinge W, van Engeland M. A Four-Gene Promoter Methylation Marker Panel Consisting of GREM1, NEURL, LAD1, and NEFH Predicts Survival of Clear Cell Renal Cell Cancer Patients. Clinical Cancer Research 2017, 23: 2006-2018. PMID: 27756787, DOI: 10.1158/1078-0432.ccr-16-1236.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAutoantigensBiomarkers, TumorCarcinoma, Renal CellDisease-Free SurvivalDNA MethylationFemaleHigh-Throughput Nucleotide SequencingHumansIntercellular Signaling Peptides and ProteinsKaplan-Meier EstimateKidney NeoplasmsMaleMiddle AgedNeurofilament ProteinsNon-Fibrillar CollagensOligonucleotide Array Sequence AnalysisPrognosisPromoter Regions, GeneticProportional Hazards ModelsUbiquitin-Protein LigasesConceptsClear cell renal cell carcinomaPrognostic modelNonmetastatic clear cell renal cell carcinomaMethylation markersCox proportional hazards modelPrimary clear cell renal cell carcinomaIndependent patient seriesCause-specific survivalOutcomes of patientsCell renal cell carcinomaPrognosis of patientsKaplan-Meier curvesLog-rank testConfidence intervalsCurrent prognostic modelsRenal cell carcinomaProportional hazards modelClin Cancer ResCcRCC cell linesCancer Genome AtlasClinicopathologic featuresPatient seriesCell carcinomaMethylation-specific PCRPoor survival
2016
Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma
Thompson ED, Zahurak M, Murphy A, Cornish T, Cuka N, Abdelfatah E, Yang S, Duncan M, Ahuja N, Taube JM, Anders RA, Kelly RJ. Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma. Gut 2016, 66: 794. PMID: 26801886, PMCID: PMC4958028, DOI: 10.1136/gutjnl-2015-310839.Peer-Reviewed Original ResearchConceptsPD-L1 expressionProgression-free survivalEpstein-Barr virusT-cell densityImmune stromaOverall survivalPD-L1T cellsAdaptive immune resistance mechanismHigh PD-L1 expressionMembranous PD-L1 expressionStromal PD-L1 expressionCD8 T cell infiltrationWorse progression-free survivalImmune resistance mechanismsImmune checkpoint inhibitorsPD-L1 positivityPD-L1 statusGastro-oesophageal junctionImmune-based therapiesT cell infiltrationPercentage of tumorsTumor-stromal interfaceCD8 densityCD8 infiltration
2015
Intraductal papillary mucinous neoplasm (IPMN) with high-grade dysplasia is a risk factor for the subsequent development of pancreatic ductal adenocarcinoma
Rezaee N, Barbon C, Zaki A, He J, Salman B, Hruban RH, Cameron JL, Herman JM, Ahuja N, Lennon AM, Weiss MJ, Wood LD, Wolfgang CL. Intraductal papillary mucinous neoplasm (IPMN) with high-grade dysplasia is a risk factor for the subsequent development of pancreatic ductal adenocarcinoma. Hepato Pancreato Biliary 2015, 18: 236-246. PMID: 27017163, PMCID: PMC4814593, DOI: 10.1016/j.hpb.2015.10.010.Peer-Reviewed Original ResearchMeSH KeywordsAgedCarcinoma, Pancreatic DuctalDatabases, FactualDisease-Free SurvivalFemaleHumansKaplan-Meier EstimateLymphatic MetastasisMaleMiddle AgedNeoplasm GradingNeoplasm InvasivenessNeoplasms, Cystic, Mucinous, and SerousNeoplasms, Second PrimaryPancreatectomyPancreatic NeoplasmsProportional Hazards ModelsRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeConceptsIntraductal papillary mucinous neoplasmHigh-grade dysplasiaPancreatic ductal adenocarcinomaNon-invasive intraductal papillary mucinous neoplasmsIntermediate-grade dysplasiaPapillary mucinous neoplasmRemnant pancreasVascular invasionMucinous neoplasmsDuctal adenocarcinomaInvasive pancreatic ductal adenocarcinomaMedian overall survivalLymph node metastasisRate of progressionSubsequent developmentIntermediate dysplasiaPancreatic resectionOverall survivalNode metastasisPerineural invasionMalignant entitiesRisk factorsPatientsDysplasiaPancreasSurvival Following Lung Metastasectomy in Soft Tissue Sarcomas
Giuliano K, Sachs T, Montgomery E, Guzzetta A, Brock M, Pawlik TM, Yang SC, Ahuja N. Survival Following Lung Metastasectomy in Soft Tissue Sarcomas. The Thoracic And Cardiovascular Surgeon 2015, 64: 150-158. PMID: 26339728, DOI: 10.1055/s-0035-1563538.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAge FactorsAgedAged, 80 and overChildChild, PreschoolDisease-Free SurvivalFemaleHumansInfantKaplan-Meier EstimateLung NeoplasmsMaleMetastasectomyMiddle AgedNeoplasm GradingPneumonectomyRetrospective StudiesRisk FactorsSarcomaSoft Tissue NeoplasmsThoracoscopyTime FactorsTreatment OutcomeYoung AdultConceptsDisease-free intervalSoft tissue sarcomasLung metastasectomyTissue sarcomasLonger disease-free intervalLower pathologic gradeMedian overall survivalKaplan-Meier estimatesLog-rank testLow-grade tumorsGreatest survival advantageOverall survivalPostoperative factorsImproved survivalPatient selectionTumor characteristicsPathologic gradeMetastasis diagnosisCommon siteSurvival advantageSurvival analysisYounger ageMetastasectomyPatientsSurvivalPromoter Methylation of CDO1 Identifies Clear-Cell Renal Cell Cancer Patients with Poor Survival Outcome
Deckers IA, Schouten LJ, Van Neste L, van Vlodrop IJ, Soetekouw PM, Baldewijns MM, Jeschke J, Ahuja N, Herman JG, van den Brandt PA, van Engeland M. Promoter Methylation of CDO1 Identifies Clear-Cell Renal Cell Cancer Patients with Poor Survival Outcome. Clinical Cancer Research 2015, 21: 3492-3500. PMID: 25904753, PMCID: PMC4612631, DOI: 10.1158/1078-0432.ccr-14-2049.Peer-Reviewed Original ResearchConceptsCDO1 promoter methylationNetherlands Cohort StudyCysteine dioxygenase type 1Prognostic markerPromoter methylationCcRCC casesRenal cell cancer patientsProspective Netherlands Cohort StudyMultivariate modelRelative prognostic valueKaplan-Meier curvesPopulation-based seriesClear cell renal cell cancer (ccRCC) patientsCurrent prognostic markersPoor survival outcomesConfidence intervalsRelevant prognostic informationIndividual patient outcomesMultivariate HRCohort studyMethylation-specific PCR analysisCancer Genome AtlasPrognostic factorsPrognostic valuePromoter methylation statusMultimodal Therapy in the Treatment of Prostate Sarcoma: The Johns Hopkins Experience
Ball MW, Sundi D, Reese AC, Meyer CF, Terezakis SA, Efron JE, Schoenberg MP, Epstein JI, Ahuja N, Bivalacqua TJ. Multimodal Therapy in the Treatment of Prostate Sarcoma: The Johns Hopkins Experience. Clinical Genitourinary Cancer 2015, 13: 435-440. PMID: 26003268, DOI: 10.1016/j.clgc.2015.04.011.Peer-Reviewed Original ResearchMeSH KeywordsChemoradiotherapy, AdjuvantDisease-Free SurvivalHumansMaleMiddle AgedNeoadjuvant TherapyProstatic NeoplasmsSurvival AnalysisConceptsCancer-specific survivalRecurrence-free survivalProstate sarcomaOverall survivalSurgical resectionLocal recurrenceMedian recurrence-free survivalFavorable cancer-specific survivalCommon presenting symptomRecords of patientsPatient demographic informationJohns Hopkins ExperienceActuarial OSConcurrent chemotherapyCurative intentMedian OSNeoadjuvant chemoradiationNeoadjuvant radiationOncological outcomesPresenting symptomMost patientsRFS ratesUrinary obstructionMetastatic recurrenceTumor characteristics
2014
A Systematic Review of Solid-Pseudopapillary Neoplasms
Law JK, Ahmed A, Singh VK, Akshintala VS, Olson MT, Raman SP, Ali SZ, Fishman EK, Kamel I, Canto MI, Dal Molin M, Moran RA, Khashab MA, Ahuja N, Goggins M, Hruban RH, Wolfgang CL, Lennon AM. A Systematic Review of Solid-Pseudopapillary Neoplasms. Pancreas 2014, 43: 331-337. PMID: 24622060, PMCID: PMC4888067, DOI: 10.1097/mpa.0000000000000061.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultCarcinoma, PapillaryDisease-Free SurvivalFemaleHumansMalePancreatectomyPancreatic NeoplasmsYoung AdultConceptsSolid pseudopapillary neoplasmSystematic reviewExcellent long-term prognosisDisease-free survivalMainstay of treatmentMean tumor sizeLong-term prognosisAbdominal painNonspecific symptomsPancreatic resectionMedian timeCommon symptomsNeoplasm casesTumor sizeMean agePatientsNumber of casesYoung womenRecurrenceNeoplasmsSymptomsMonthsTotalPainResection
2013
Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases
Karagkounis G, Torbenson MS, Daniel HD, Azad NS, Diaz LA, Donehower RC, Hirose K, Ahuja N, Pawlik TM, Choti MA. Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases. Cancer 2013, 119: 4137-4144. PMID: 24104864, PMCID: PMC3967132, DOI: 10.1002/cncr.28347.Peer-Reviewed Original ResearchConceptsColorectal liver metastasesSurgical therapyBRAF mutationsLiver metastasesKRAS statusPrognostic impactKRAS mutationsMolecular biomarkersThird of patientsRecurrence-free survivalKRAS gene mutationsPrognostic determinantsColorectal metastasesSurgical cohortWorse survivalClinicopathologic factorsIndependent predictorsCancer surgeryClinicopathologic featuresTumor numberPrognostic significanceBRAF analysisColorectal cancerLiver surgeryLower incidence
2012
Epithelioid sarcoma: one institution's experience with a rare sarcoma
Guzzetta AA, Montgomery EA, Lyu H, Hooker CM, Meyer CF, Loeb DM, Frassica D, Weber KL, Ahuja N. Epithelioid sarcoma: one institution's experience with a rare sarcoma. Journal Of Surgical Research 2012, 177: 116-122. PMID: 22575361, PMCID: PMC3715113, DOI: 10.1016/j.jss.2012.04.030.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedChildDisease-Free SurvivalFemaleHumansMaleMarylandMiddle AgedNeoplasm Recurrence, LocalSarcomaYoung AdultConceptsEpithelioid sarcomaOverall survivalDiagnosis of ESRegional lymph node metastasisRare soft tissue sarcomaAvailable histological slidesCentralized cancer registryMedian overall survivalNumber of resectionsInstitutional review board approvalRegional nodal basinLymph node metastasisSoft tissue sarcomasNumber of recurrencesMajority of tumorsReview board approvalJohns Hopkins Medical InstitutionsRepeated ResectionMedian ageMost patientsMedian timeNode metastasisPatient chartsCancer RegistryInstitution experience